HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

A CAR-T biotech’s dramatic turnaround, and drugmakers’ tactics to drive more scripts

This week on "The Readout LOUD": a CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts. Listen now.

By STAT News · Apr 23, 2026 · via STAT News
A CAR-T biotech’s dramatic turnaround, and drugmakers’ tactics to drive more scripts

Image: STAT News

This is an aggregated industry headline. Read the full story at STAT News →

Tags
pipelineformat:headlineheadlineSTAT News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
Sanofi gains long-awaited win for tolebrutinib as EU regulator endorses MS drug for approval
PipelineFiercePharma ↗
Sanofi gains long-awaited win for tolebrutinib as EU regulator endorses MS drug for approval
After a series of setbacks for Sanofi’s tolebrutinib, the French company has scored a victory for the multiple…
Apr 26, 2026
Regeneron ushers in new genetic medicine era with groundbreaking gene therapy approval
PipelineFiercePharma ↗
Regeneron ushers in new genetic medicine era with groundbreaking gene therapy approval
Travis Smith was a very serious baby. Born completely unable to hear, his mother, Sierra, struggled to see his…
Apr 25, 2026
Novartis pulls Pluvicto prostate cancer label expansion filing in the EU
PipelineEndpoints News ↗
Novartis pulls Pluvicto prostate cancer label expansion filing in the EU
Novartis has withdrawn its EU application for Pluvicto's expansion into earlier prostate cancer treatment, des…
Apr 24, 2026